Skip to main navigation Skip to search Skip to main content

Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7)

  • Inge van der Werf*
  • , Anna Wojtuszkiewicz
  • , Huilan Yao
  • , Rocco Sciarrillo
  • , Manja Meggendorfer
  • , Stephan Hutter
  • , Wencke Walter
  • , Jeroen Janssen
  • , Wolfgang Kern
  • , Claudia Haferlach
  • , Torsten Haferlach
  • , Gerrit Jansen
  • , Gertjan J. L. Kaspers
  • , Richard Groen
  • , Gert Ossenkoppele
  • , Jacqueline Cloos
  • *Corresponding author for this work
  • Amsterdam UMC - University of Amsterdam
  • H3 Biomedicine, Inc, Boston, MA, USA
  • Munich Leukemia Laboratory
  • Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, The Netherlands
  • Vrije Universiteit Amsterdam

Research output: Contribution to journalComment/Letter to the editorAcademic

16 Downloads (Pure)

Abstract

Despite carefully proofreading our submission, we missed a mistake in the affiliation of Wolfgang Kern, Claudia Haferlach and Torsten Haferlach. Instead of (2) H3 Biomedicine, their affiliation should be (3) MLL Munich Leukemia Laboratory, Munich, Germany.
Original languageEnglish
Pages (from-to)2735
Number of pages1
JournalLeukemia
Volume35
Issue number9
DOIs
Publication statusPublished - 1 Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7)'. Together they form a unique fingerprint.

Cite this